Artichoke
Artichoke bract extract is useful against liver and gallbladder disorders and as a hepatoprotective, choleretic and hypolipidemic agent. The beneficial and therapeutic activity is mainly attributed to the presence of caffeoylquinic acids and flavones. In addition, artichoke bracts are a great source of inulin (18-36% of dry matter), a fructose-based polysaccharide with specific prebiotic properties. Several studies suggest that the hepatoprotective effect of artichoke extracts is due to their antioxidant activity7-8. Artichoke leaf extracts showed antioxidant action against hydroperoxide-induced oxidative stress on cultured rat hepatocytes, HepG28 human hepatoma cells, and human leukocytes10.
Triphala
Gastrointestinal Health. Gastrointestinal health represents perhaps Triphala’s best-known target. In vivo studies have shown that Triphala extracts prevent diarrhea11 and induce enteroprotective effects by both enhancing intestinal villi function and glutathione and phospholipid levels12. In other studies in rats, Triphala exerted a gastroprotective effect on stress-induced ulcer13. A clinical study evaluated the use of Triphala in patients with gastrointestinal disorders, the authors report that the treatment reduced constipation, mucus, abdominal pain, hyperacidity and flatulence by improving stool frequency, yield and consistency14. Triphala also reduced colitis in a mouse model, an effect attributed to its high antioxidant potential15.
Antiobesogenic potential of Triphala. Several studies have demonstrated the potential of Triphala as a therapeutic agent for weight loss and body fat reduction. In an in vivo study, Triphala was administered for 10 weeks to diet-induced obese mice16. Triphala treatment reduced the percentage of body fat and body weight. Triphala also reduced total cholesterol, triglycerides, and low-density lipoproteins in the experimental group compared with the control group. In a 12-week, double-blind, randomized, placebo-controlled clinical trial, Triphala-treated subjects lost 5 kg compared with the placebo control group17. Treated subjects also showed reductions in fasting blood glucose and serum insulin levels compared with control subjects.
Antidiabetic activity. Several studies have demonstrated the potential of Triphala as a hypoglycemic phytotherapeutic. A first effect is due to Triphala’s ability to inhibit the pancreatic glycolytic enzymes, alpha-amylase and alpha-glucosidase, which cleave complex polysaccharides into glucose molecules17. They act in this way by reducing blood glucose levels, and this effect is particularly expected in patients with type 2 diabetes who usually have high postprandial blood glucose levels. A clinical study of patients with non-insulin-dependent diabetes mellitus revealed that supplementation with 5 g of Triphala powder for 45 days significantly reduced blood glucose levels18, as well as fasting and postprandial blood glucose. Triphala constituents, including ellagitannins and gallotannins, are PPAR α and γ agonists, which increase insulin response and glucose uptake without inducing adipogenesis19, promoting reduced blood glucose in diabetic patients. This also suggests a direct mechanism of Triphala in activating through PPARα genes involved in oxidative fatty acid metabolism resulting in both hepatic and blood level reduction of triglycerides.